DeutschNewstral
Article
Mmarketwatch.com on 2019-05-28 13:06
Mallinckrodt to spin off specialty generics business in second half
Related news
- MShares of Mallinckrodt Pharmaceuticals up 0.5% after company announces generics business spin-offmarketwatch.com
Mallinckrodt to spin off generic drugs business; specialty drugs to be based in New Jerseybizjournals.com
Specialty Generics: Barriers To UptakeForbes- Mallinckrodt reaches $1.6B opioid settlement calling for generics unit bankruptcybizjournals.com
- Mallinckrodt consolidating specialty brands to New Jerseybizjournals.com
Mallinckrodt Enters Creditor Talks Ahead of Potential Generics Bankruptcywsj.com- Mallinckrodt details generic drug spin off, renames speciality drug companybizjournals.com
- Specialty Generics Face A Maze Of Perverse Incentives In Medicare Part DForbes
- KSpecialty Injectable Generics Market to Discern Steadfast Expansion During 2021-2026ksusentinel.com
- Mallinckrodt stock soars as second quarter earnings releasedbizjournals.com
AkzoNobel plans to spin off Specialty Chemicals unitMerced Sun-Star
TEST SPIN | Rostam — Half-Lightcornellsun.com- USpin This: The Second Editionunfspinnaker.com
- MMallinckrodt stock drops 8% on new Citron Research reportmarketwatch.com
- MMallinckrodt to sell BioVectra business for $250 million, stock surgesmarketwatch.com
- Stock Market Strategies: Best ETF And Mutual Fund Ideas For Second-Half 2017Forbes
- MMallinckrodt shares drop 8.6% after Q3 profit, revenue missesmarketwatch.com
- MSucampo Pharmaceuticals' stock surges after Mallinckrodt buyout dealmarketwatch.com
- FCommentary: Second half team?flathatnews.com
- TSecond half previewthebruns.ca